Nonalbuminuric CKD May Increase Mortality in Type 1 Diabetes

This article originally appeared here.
Nonalbuminuric chronic kidney disease was linked to increases in all-cause and cardiovascular mortality, but not albuminuria or end-stage renal disease.
Nonalbuminuric chronic kidney disease was linked to increases in all-cause and cardiovascular mortality, but not albuminuria or end-stage renal disease.

(HealthDay News) -- Nonalbuminuric chronic kidney disease is associated with increased risk of cardiovascular disease and all-cause mortality, but not renal outcomes, in patients with type 1 diabetes, according to a study published online in Diabetes Care.

Lena M. Thorn, M.D., from the Folkhälsan Institute of Genetics in Helsinki, and colleagues conducted an observational follow-up of 3,809 patients with type 1 diabetes from the Finnish Diabetic Nephropathy Study. The authors examined the prevalence of nonalbuminuric chronic kidney disease and its impact on cardiovascular and renal outcomes and mortality.

The researchers found that 2.0% of patients had nonalbuminuric chronic kidney disease at baseline. This correlated with older age, female sex, retinal laser treatment history, cardiovascular events, and number of antihypertensive drugs in use; there was no correlation with blood pressure levels or specific antihypertensive agents. Nonalbuminuric chronic kidney disease was not associated with increased risk of albuminuria (hazard ratio [HR], 2.0; 95% confidence interval [CI], 0.9 to 4.4) or end-stage renal disease (HR, 6.4; 95% CI, 0.8 to 53.0), but did correlate with increased risk of cardiovascular events (HR, 2.0; 95% CI, 1.4 to 3.5) and all-cause mortality (HR, 2.4; 95% CI, 1.4 to 3.9).

"Nonalbuminuric chronic kidney disease is not a frequent finding in patients with type 1 diabetes, but when present, it is associated with an increased risk of cardiovascular morbidity and all-cause mortality but not with renal outcomes," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which partially funded the study.

Source

  1. Thorn, LM; Gordin, D; Harjutsalo, V; et al. Diabetes Care, August 26, 2015, published online before print; doi: 10.2337/dc15-0641.
Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup